Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world effectiveness and safety of trifluridine/tipiracil plus bevacizumab in metastatic colorectal cancer
jRCT1031220116Completed
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Start
- Jun 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Open-label trial of trifluridine + tipiracil, bevacizumab and regorafenib in colorectal cancer (CRC) (3 arms), sponsored by Taiho Pharmaceutical Co., Ltd. Primary endpoint: overall survival. Started Jun 2022; status: completed.
02
Drugs
trifluridine + tipiracilbevacizumabregorafenib
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on jRCT1031220116.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1031220116.